|
| Wednesday, 28 June 2023, 22:00 HKT/SGT | |
| |  | |
來源 Lane | |
|
|
|
|
| PassFax boasts a low monthly cost, making the service highly advantageous for both businesses and individuals |
聖安東尼奧，德克薩斯州, 2023年6月28日 - (亞太商訊) - Lane, a distinguished provider of innovative faxing solutions, has announced its latest product, PassFax, which promises to transform how businesses and individuals send and receive faxes within its platform. Powered by Lane's flagship product, Passport, PassFax is a versatile and flexible solution that caters to the needs of various individual users and businesses.
With PassFax, users can easily send and receive faxes from any location with an internet connection. The product offers a web user interface, making it easy for users to exchange faxes at a comparatively low cost. This level of convenience eliminates the inefficiencies of traditional fax machines and allows businesses and individuals to save time and money while streamlining their fax communications.
"We've designed PassFax to be an affordable and easy-to-use tool that helps businesses and individuals save time and money while improving overall productivity," states the CEO of Lane, Liz Maya. "We are thrilled to bring this product to an increasingly competitive market to help fax users stay ahead of the curve in our ever-evolving digital age."
PassFax offers basic, business, and enterprise packages to suit both business and individual communication needs. The product comes with customizable options that enable users to tailor it to their unique communications environment. For as low as $9.95 a month, users can enjoy the benefits of reliable and affordable online faxing.
By introducing this new online faxing solution, Lane is making it simpler than ever for businesses and individuals to keep up with their document-sharing needs without compromising affordability, security, or convenience.
About Lane
Lane is recognized globally as a leader in secure messaging communications and fax integration across a wide range of industries. Lane aims to exceed expectations by applying robust and tailored solutions that yield tangible results for their clients. With a strong track record of implementing systems across 50 countries, Lane's team possesses extensive knowledge and experience in developing solutions from the largest financial institutions to healthcare companies, as well as other public and private enterprises. For more information, visit https://laneds.com, call us at +1 (973) 526-2979, or email us at info@lanetelecom.com.
Contact Information
Liz Maya
CEO
lmaya@lanetelecom.com
話題 Press release summary
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Gench Education Announces 2025 Annual Results
Mar 28, 2026, 15:43 HKT/SGT
|
|
|
Vantage Goldfields Corrects Misleading Announcement by Lions Bay Capital Inc. (LBI)
Mar 28, 2026, 06:26 HKT/SGT
|
|
|
Shoucheng Holdings (0697.HK) Proposes HK$780 Million Dividend: HK$6 Billion in Cumulative Payouts Over Eight Years Solidifies Long-Term Value Logic
Mar 27, 2026, 23:00 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 27, 2026, 19:40 HKT/SGT
|
|
|
Xunce Technology's Revenue Surges 449% Half-on-Half: Is a Structural Revaluation to a Hundred-Billion Market Cap Camp on the Horizon? 
Mar 27, 2026, 19:19 HKT/SGT
|
|
|
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Friday, March 27, 2026 7:14:00 PM
|
|
|
Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility
Friday, March 27, 2026 6:44:00 PM
|
|
|
Analogue 2025 Annual Results Profit Attributable to Owners of the Company Increases 23.5% to HK$167.0 Million
Mar 27, 2026, 18:38 HKT/SGT
|
|
|
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Friday, March 27, 2026 5:19:00 PM
|
|
|
New "L00 Series" Train for the Seibu Railway's Yamaguchi Line Begins Commercial Operation
Friday, March 27, 2026 3:51:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
